Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.56 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3583116 | 0.99 | HRH3 (0.61) | HRH3KCNH2TLR9TLR7MAPT | |
| SCHEMBL3580230 | 0.97 | HRH3 (0.59) | HRH3KCNH2TLR9TLR7MAPT | |
| SCHEMBL3584340 | 0.94 | HRH3 (0.60) | HRH3KCNH2ALDH1A1 | |
| SCHEMBL21659288 | 0.91 | HRH3 (0.58) | HRH3KCNH2TLR9TLR7MAPT | |
| SCHEMBL3579113 | 0.88 | KDM4E (0.55) | HRH3TLR9TLR7ALDH1A1EPHX2 | |
| SCHEMBL5935409 | 0.87 | HRH3 (0.67) | HRH3KCNH2ALDH1A1KDM4E | |
| SCHEMBL22776398 | 0.86 | MAPT (0.58) | MAPTALDH1A1KDM4ELMNA | |
| SCHEMBL3572470 | 0.86 | HRH3 (0.65) | HRH3MAPTALDH1A1GAA | |
| SCHEMBL2850901 | 0.86 | HRH3 (0.63) | HRH3MAPTPOLBEPHX2 | |
| SCHEMBL21659284 | 0.85 | MAPT (0.53) | HRH3MAPTALDH1A1EPHX2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075953-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| US-20100004241-A1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-07 | — | — | US | disclosed |
| US-20100004241-A1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-07 | — | — | US | disclosed |
| US-20100004241-A1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-07 | — | — | US | disclosed |
| US-7615550-B2 | Substituted piperazines,(1,4) diazepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists | GLAXO GROUP LIMITED (GB) | 2009-11-10 | — | — | US | disclosed |
| US-20080306085-A1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES | APODACA RICHARD | 2008-12-11 | — | — | US | disclosed |
| US-20080306085-A1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES | APODACA RICHARD | 2008-12-11 | — | — | US | disclosed |
| US-20080306085-A1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES | APODACA RICHARD | 2008-12-11 | — | — | US | disclosed |
| US-7429586-B2 | Non-imidazole aryloxyalkylamines | ORTHO-MCNEIL PHARMACEUTICLAS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429586-B2 | Non-imidazole aryloxyalkylamines | ORTHO-MCNEIL PHARMACEUTICLAS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429586-B2 | Non-imidazole aryloxyalkylamines | ORTHO-MCNEIL PHARMACEUTICLAS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7186732-B2 | Non-imidazole aryloxyalkylamines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186732-B2 | Non-imidazole aryloxyalkylamines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186732-B2 | Non-imidazole aryloxyalkylamines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20060235049-A1 | 1-{3-[4-(1-Methyl-pyrrolidin-2-yl)-phenoxy]-propyl}-piperidine, and 1-Benzyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperidin-4-ol; histamin receptor antagonist; antidepressant; upper airway allergies, nasal congestion, allergic rhinitis, cognitive dysfunction, schizophrenia, manic disorders | APODACA RICHARD | 2006-10-19 | — | — | US | disclosed |
| EP-1313721-B1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20060025404-A1 | Substituted piperazines,(1,4) diaszepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| EP-1313721-A2 | NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020065278-A1 | Non-imidazole aryloxyalkylamines | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2002012214-A2 | NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025404-A1 | Substituted piperazines,(1,4) diaszepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 282/4885TLR9 3890/4885 |
| US-20020065278-A1 | Non-imidazole aryloxyalkylamines | HNMT, HRH2, HRH3 | HRH3 3/4885KCNH2 470/4885TLR9 371/4885 |
| US-20100075953-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 352/4885TLR9 3850/4885 |
| US-20060235049-A1 | 1-{3-[4-(1-Methyl-pyrrolidin-2-yl)-phenoxy]-propyl}-piperidine, and 1-Benzyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperidin-4-ol; histamin receptor antagonist; antidepressant; upper airway allergies, nasal congestion, allergic rhinitis, cognitive dysfunction, schizophrenia, manic disorders | HRH4, HRH3, HRH2 | HRH3 2/4885KCNH2 1178/4885TLR9 339/4885 |
| US-20100004241-A1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES | HNMT, HRH2, HRH3 | HRH3 3/4885KCNH2 470/4885TLR9 371/4885 |
| US-20080306085-A1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES | HNMT, HRH2, HRH3 | HRH3 3/4885KCNH2 470/4885TLR9 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.